Dr. Fleming is the chair and program director of the department of gastrointestinal oncology at Moffitt Cancer Center and a recognized leader in the treatment of gastrointestinal cancers. He initiated and developed the first direct xenograft program in gastrointestinal cancer at MD Anderson, providing a unique platform to examine pancreatic adenocarcinoma and to test new drug candidates for the treatment of pancreatic cancer. Prior to joining Moffitt, He was a professor in the department of surgical oncology at the University of Texas MD Anderson Cancer Center, where he served as chief of pancreas surgery and executive director of perioperative services.
Beyond his academic obligations, Dr. Fleming serves as an editor for numerous scientific journals including the Journal of Surgical Education, and serves on the editorial board of the Self-Assessment Program (SESAP) for the American College of Surgeons. During his career, he has written more than 130 peer-reviewed articles and 14 books. In addition, he has been recognized as a Castle Connolly Top Doctor since 2013 and included in the Consumer Research Council of America Guide to America’s Top Surgeons since 2012.
Dr. Fleming received his M.D. from the University of Tennessee Center of Health Science. He completed his clinical residency in general surgery at the University of Texas Southwestern Medical Center, a fellowship at the University of Texas Southwestern Medical Center and a clinical fellowship in surgical oncology at the University of Texas MD Anderson Cancer Center.